SPIMACO Pharmaceutical Company announced today on tadawul acquiring 48% interest in EirGen pharma Ltd.; An Irish company in the business of producing and developing High Potency Cytotoxic Pharmaceutical Products.
The deal is valued at EUR 19m equivalent to SAR 93m and is financed by the company’s internal resources.
Comments
{{DisplayName}}
{{ElapsedTime}}